Video

Dr. Yardley on BOLERO-2 Results for HR+ Breast Cancer

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

According to Yardley, hormone resistance is an important area for patients with HR-positive breast cancer. Data from the BOLERO-2 study made the combination of everolimus (Afinitor) and exemestane a standard of care for patients who were failing endocrine therapy.

Additionally, CDK4/6 inhibitors have rolled out in advanced patients in the second-line setting, explains Yardley.

Related Videos
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma